SEC Form 4 · accession 0001179110-17-015438

AbbVie Inc. · ABBV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Executive Vice President

Period of report

Dec 14, 2017

Accepted (ET)

Dec 15, 2017 · 5:13 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001551152

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common stock, $0.01 par value	Dec 14, 2017	M	144,367	$35.88	A	250,099	D
Common stock, $0.01 par value^F1	Dec 14, 2017	S	144,367	$96.7068	A	105,732	D
Common stock, $0.01 par value	Dec 15, 2017	M	1,143	$35.88	A	106,875	D
Common stock, $0.01 par value	Dec 15, 2017	S	1,143	$96.86	A	105,732	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option (right to buy)^F2	$35.88	Dec 14, 2017	M	144,367	D	Feb 14, 2016	Feb 13, 2023	Common stock	144,367	1,143	D
Option (right to buy)^F2	$35.88	Dec 15, 2017	M	1,143	D	Feb 14, 2016	Feb 13, 2023	Common stock	1,143	0	D

F1The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.50 to $97.44, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).